#Spain #Madrid #Sandoz #mAbxience #emicizumab

Collaboration Announcement

Introduction
mAbxience, a prominent player in the biopharmaceutical sector, has recently entered into a significant collaboration with Sandoz to advance the accessibility of biosimilars worldwide. This partnership combines mAbxience’s expertise in development and manufacturing with Sandoz’s global commercial capabilities, particularly in relation to a proposed emicizumab biosimilar candidate.

The Importance of Biosimilars

Biosimilars hold immense potential in transforming the healthcare landscape by providing patients with affordable alternatives to expensive biologic medicines. As biologics come off patent, the demand for high-quality biosimilars is expected to surge. The collaboration aims to tap into this growing market, particularly targeting conditions like hemophilia A, which is characterized by a deficiency of factor VIII, essential for blood clotting.

Details of the Collaboration

Under the terms of the agreement, mAbxience will oversee the comprehensive development and manufacturing process of the emicizumab biosimilar at its state-of-the-art facilities located in Spain and Argentina. Meanwhile, Sandoz will retain exclusive global commercialization rights, excluding regions such as Argentina, Uruguay, and Paraguay. Although the financial specifics of the collaboration are kept private, its implications for patient access are significant.

Addressing Unmet Medical Needs

Hemophilia A affects a considerable number of individuals globally, with nearly 80% of all hemophilia cases falling under this category. The collaboration is crucial, as it seeks to meet the pressing medical needs of these patients by providing access to effective treatment options that are both high-quality and affordable. The global reference market for emicizumab is valued at approximately USD 5.7 billion, making this collaboration not only timely but also strategically beneficial for both companies.

Vision for the Future

Jurgen Van Broeck, CEO of mAbxience, expressed confidence in the partnership stating, “This agreement represents a significant recognition of our capabilities and the expertise of our teams.” He emphasized that the collaboration does not only strengthen mAbxience’s position in the competitive biosimilars market but also reflects a commitment to provide better access to high-quality biologic medicines to patients worldwide.

Broader Implications

The collaboration with Sandoz is part of mAbxience’s broader strategy to expand its biosimilar pipeline, which encompasses oncology, immunology, bone diseases, and more. As healthcare systems brace for an influx of biologic products losing exclusivity, the timing of this agreement could not be better, paving the way for innovative treatments to enter the market.

Conclusion

The partnership between mAbxience and Sandoz symbolizes a forward-thinking approach in the biopharmaceutical industry. By combining forces, they will not only enhance their reach and capabilities but also contribute significantly to improving patient access to essential therapies. This alliance not only marks a crucial step for both companies but also heralds a new era for biosimilars in patient care around the globe.